Mevrometostat clinical trials
Also written PF-06821497.
How each study uses mevrometostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the mevrometostat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 1
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 2 in phase 3
Studies that test mevrometostat, phase 3 first.
- Feb 2027A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).Phase 3 · Pfizer
- Sep 2027A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.Phase 3 · Pfizer
Studies
Open first, then newest update. How each study uses mevrometostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.RecruitingPhase 3PfizerNCT06629779Written as PF-06821497
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaRecruitingPhase 1PfizerNCT03460977Written as Mevrometostat (PF-06821497)
- This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.RecruitingPhase 3PfizerNCT07028853Written as Mevrometostat
- A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor TherapyNot yet recruitingPhase 2Prostate Cancer Clinical Trials ConsortiumNCT07592910Written as Mevrometostat
- A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).Active, not recruitingPhase 3PfizerNCT06551324Written as PF-06821497
- A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.CompletedPhase 1PfizerNCT05767905Written as PF-06821497 Treatment A
- A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy AdultsWithdrawnPhase 1PfizerNCT06661694Written as Treatment A
- A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.CompletedPhase 1PfizerNCT06392230Written as Oral [14C] PF-06821497
Codes
What other systems call mevrometostat · ClinicalTrials.gg INT017852
- UNII (FDA) S4L4MM20B6MEVROMETOSTATConfirmed FDA, Wikidata
- Wikidata Q29209799mevrometostatConfirmed FDA, Wikidata
- NCI Thesaurus C156743MevrometostatOne source FDA
- DrugBank DB14799One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | S4L4MM20B6 | MEVROMETOSTAT | Confirmed FDA, Wikidata |
| Wikidata | Q29209799 | mevrometostat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C156743 | Mevrometostat | One source FDA |
| DrugBank | DB14799 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.